Publications
321
Citations
13,039
Est. group size
~14
Recurring co-author estimate
Active years
23
Publishing since 2004
Typically publishes in teams of ~12 · 5% small-team papers (≤3 authors) · across 42 venues
- Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study
Nature Communications · 2026
- An analysis of palliative care in adolescents and young adults with soft tissue and bone sarcomas
Palliative Care and Social Practice · 2026
- Investigating vimseltinib in tenosynovial giant cell tumors
Expert Opinion on Pharmacotherapy · 2026
- 84MO Phase I study of the tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) combined with irinotecan (I) and temozolomide (T) in adolescents and adults with Ewing sarcoma
ESMO rare cancers. · 2026
- Abstract 1151: Targeting high risk osteosarcoma: MYC modulation alters metastasis
Cancer Research · 2026
- Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial
Nature Medicine · 2026
- Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
Cancer Research Communications · 2025
- Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage Activation
JCO oncology advances. · 2025
- Desmoid tumor control with liposomal doxorubicin: a dual-center retrospective analysis
Expert Review of Anticancer Therapy · 2025
- Thematic Analysis of Clinician Documentation Surrounding Treatment Discussions and Decision‐Making in Patients With Desmoid Tumors
Cancer Medicine · 2025
- A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).
Journal of Clinical Oncology · 2025
- Subgroup analysis of the phase 2 part of the RINGSIDE phase 2/3 trial of varegacestat for treatment of desmoid tumors.
Journal of Clinical Oncology · 2025
- Change in T2-weighted signal intensity, change in tumor volume, and exposure-response analysis in the RINGSIDE phase 2 study of varegacestat in patients with desmoid tumors.
Journal of Clinical Oncology · 2025
- Abstract B048: The Ewing Sarcoma Institute – a catalyst to improve outcomes for patients with Ewing sarcoma globally
Cancer Research · 2025
- A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors
Future Oncology · 2025
- Journal of Clinical Oncology×46
- Annals of Oncology×9
- Cancer Research×8
- Cancer×7
- Clinical Cancer Research×5
- Scott M. Schuetze
Medicine · University of Michigan
- David R. Lucas
Medicine · University of Michigan
- David A. Liebner
Medicine · The Ohio State University
- Denise K. Reinke
Medicine · University of Michigan
- Scott Lenobel
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile